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Abstract: We evaluate how 3-acetylation modulates the in vitro activity of ursolic acid in melanoma
cells alone or in combination treatments with quercetin. Anti-proliferative studies on A375 cells
and adult human dermal fibroblasts included analyses on cell cycle distribution, caspase activity,
phosphatidylserine translocation, cell morphology and Bax/Bcl-2 protein expression. Then, 2D
and 3D migration of B16F10 cells were studied using scratch and Transwell assays, respectively.
Ursolic acid and 3-O-acetylursolic acid have shown similar GI50 on A375 cells (26 µM vs. 32 µM,
respectively) significantly increased both early and late apoptotic populations, activated caspases
3/7 (48–72 h), and enhanced Bax whilst attenuating Bcl-2 expression. Ursolic acid caused elevation
of the sub-G1 population whilst its 3-acetyl derivative arrested cell cycle at S phase and induced
strong morphological changes. Combination treatments showed that ursolic acid and quercetin act
synergistically in migration assays but not against cell proliferation. In summary, 3-O-acetylursolic
acid maintains the potency and overall apoptotic mechanism of the parent molecule with a more
aggressive influence on the morphology of A375 melanoma cells but the 3-acetylation suppresses its
anti-migratory properties. We also found that ursolic acid can act in synergy with quercetin to reduce
cell migration.
Keywords: pentacyclic triterpenes; apoptosis; melanoma; migration; cell cycle; synergism
1. Introduction
Pentacyclic terpenes such as betulinic acid, lupeol, ursolic acid, and oleanolic acids have been
described as highly specific cytotoxic drugs against several cancer cells [1–5].
The effects of ursolic acid on melanoma cells has been gaining interest for its cytotoxic with a
favourable selectivity index [6–8]. Moreover, it also suppresses the migration of malignant melanoma
cells [9]. Clinical tests suggesting the possibility of practical use of ursolic acid have already been
conducted [10].
Derivatization of terpenoids might improve its cytotoxicity. In the case of ursolic acid,
the anti-proliferative effect was improved when a hydrogen acceptor group was introduced to
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positions 3, 11, 17 and 28 like acetyl or aminoalkyl groups, with β-oriented hydrogen-bond forming
groups at C-3 exhibiting more potent cytotoxicity than theirα-counterparts (Figure 1) [11–14]. However,
modification at position 28, namely amidation and esterification carboxylic acid, led to a decrease of its
selectivity index [15].
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The simplicity of the 3-acetyl derivative, commonly referred to as acetylursolic acid or
3-O-acetylursolic acid, makes it a good candidate for further mechanistic studies and has not yet
been studied for its anti-migratory activities. Previous works studied the semisynthetic product.
It seems that 3-O-acetylursolic acid is scarce in nature as it has been seldom isolated. Some of its
reported sources are the aerial roots of Ficus microcarpa (Moraceae), the leaves of Carissa spinarum L.
(Apocynaceae) [16], and the aerial parts of Strumpfia maritima Jacq. (Rubiaceae) [17].
Another way to increase the apoptotic and anti-migratory effects of ursolic acid is by combination
with a synergic drug. Quercetin is a secondary metabolite that is known for its anti-migratory activity
and shown synergistic activity with sulforaphane [18]. Many studies suggest that ursolic acid and
quercetin not only can be used as cancer chemosensitizers to standard chemotherapeutic drugs but
also as chemoprotective and radioprotective thus protecting normal cells [19,20]. Their combination
would, therefore, provide notable advantages in anticancer treatment.
Therefore, we here aim to contribute to the current knowledge of the effects of pentacyclic
triterpenes acids on melanoma cells by studying the antimigratory activity and pro-apoptotic
mechanisms of its 3-acetyl derivative as well as the effects of combinatorial treatments of ursolic acid
and quercetin on cell proliferation and 2D/3D migration.
2. Materials a d Methods
2.1. Materials
Ursolic acid and its acetate were isolated as previously described [16]. Other chemicals were
purchased from Sigma-Aldrich (St. Louis, MO, USA): ursolic acid (≥90%) and quercetin (≥90%),
Sulforhodamine B, trichloroacetic acid, Trizma base, propidium iodide, Ribonuclease A, formaldehyde,
and crystal violet. Glacial acetic acid, ethanol, and methanol were obtained from Fisher (Leicestershire,
UK). Dulbecco’s modified eagle media (DMEM), minimum essential media (MEM), heat-inactivated
fetal bovine serum (FBS), penicillin-streptomycin antibiotic, non-essential amino acids solution (NEAA),
TrypLE Express (1×, trypsin, EDTA, phenol red), phosphate-buffered saline (PBS), ReadyProbes®
cell viability imaging kittrypan blue were purchased from Thermo Fisher Scientific (Waltham, MA,
USA). Matrigel was purchased from BD Bioscience (San Jose, CA, USA), SDS-PAGE gel from Bio-Rad
(Hercules, CA, USA), Caspase-Glo® 3/7 fro Promega, Annexin V-FITC kit from Miltenyi Biotec and
Bax, Bcl-2 and β-actin proteins from Cell Signaling Technology (Danvers, MA, USA).
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2.2. Cell Lines
A375 (human malignant melanoma) and B16-F10 (murine malignant melanoma) cell lines were
purchased from American Type Culture Collection (Manassas, VA, USA) and HDf-a (primary adult
human dermal fibroblasts) from Thermo Fisher Scientific (Waltham, MA, USA). A375 and HDf-a were
used to study the cytotoxicity and selectivity of compounds and B16-F10 cell line was used in the
scratch and Boyden chamber assays. A375 cells were maintained in DMEM and supplemented with
10% FBS and 1% penicillin-streptomycin antibiotic. HDf-a cells were grown in MEM supplemented
with 10% FBS, 1% MEM-NEAA, and 1% antibiotic solution. The media used to maintain B16-F10 was
MEM, supplemented with 10% FBS and 1% of the antibiotic solution. All cell lines were cultured in
complete growth medium (10% FBS) and incubated in an incubator with humidified air 5% CO2 and
atmosphere at 37 ◦C.
2.3. Sulforhodamine B (SRB) Assay
This assay was conducted as previously described [21], A375 and HDF-a cells were seeded in a
96-well microtiter plate at a density of 10,000 cells per well to allow the cells to attach to the plate. Then,
cells were treated with different concentrations of isolated compounds with vehicle control (DMSO)
which had been previously prepared in 10% culture medium. The cells were incubated in the incubator
for 24, 48, and 72 h and periodically checked using an inverted microscope. Later, the cells were fixed
with cold 40% trichloroacetic acid (TCA) solution, to achieve the final concentration of 10%. The plates
were incubated at 4 ◦C for 1 h and then rinsed five times with water. The TCA-fixed cells were stained
by adding Sulforhodamine B solution (0.4% SRB in 0.1% acetic acid) and left at room temperature for
1 h. Afterwards, the plates were quickly rinsed four times with 1% acetic acid and flicked to remove
the unbound dye and then left to air-dry overnight. The bounded stain was solubilised by adding
10 mM Tris base buffer solution to each well. The optical density was measured at 510 nm by using a
microtiter plate reader (Infinite® M200, Tecan, Switzerland). The data was normalized to untreated
wells, GI50 value was calculated as the concentration that results in 50% cell growth inhibition and
graphs were drawn on OriginPro software.
2.4. Cell Cycle Analysis
The cell distribution at different stages of the cell cycle was measured through cellular DNA
analysis and performed using A375 cells according to the method of Li and colleagues [22]. The cells
were seeded at a density of 500,000 cells in serum-free medium in a 6-well plate and left to attach in
the incubator at 37 ◦C overnight. Compounds and DMSO in 10% growth media were added after
removing the old media and incubated for 48 h. Afterwards, cells were washed with PBS and detached
by adding TrypLE and combined with floated cells. Then, the cell suspension was centrifuged and
washed twice with PBS. Later, cells were fixed by cold 70% ethanol in PBS and incubated for 18 h at 4 ◦C.
After removing the ethanol, the cells were washed and treated with 100 µg/mL of RNase for 30 min.
In the dark, they were stained with propidium iodide (PI) solution, 50 µg/mL of PI dissolved in PBS,
and incubated for 10 min. The sample was analysed by MACSQuant Analyzer and MACSQuantify™
software (Miltenyi Biotech, Germany). The assay was carried out in three independent experiments
(mean ± SD, n = 3).
2.5. Apoptosis Induction Analysis by Flow Cytometry
Analysis of phosphatidylserine translocation was performed using Annexin V-FITC kit according
to the manufacturer’s instructions (Miltenyi Biotec, Germany). Around 250,000 of A375 cells were
seeded in a 12-well plate overnight. Later, 10% growth media containing compound and DMSO were
added and incubated for 12 and 24 h at 37 ◦C. After the end of the incubation period, cells were
detached using TrypLE and washed with PBS and next with the binding buffer. Then, the cell pellet
was resuspended in binding buffer containing Annexin V-FITC and incubated for 15 min in the dark at
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room temperature. Later, cells were incubated with binding buffer containing 1 µg/mL of propidium
iodide (PI) solution immediately before analysis by flow cytometry. The MACSQuant® Analyzer was
used for data acquisition and the MACSQuantify software for data analysis and data was applied from
three independent experiments across different cell passages (mean ± SD, n = 3).
2.6. Caspase-3/7 Activity Assay
The apoptosis induced by compounds was determined by measuring the activity of caspases-3/7
using Caspase-Glo® 3/ according to the manufacturer’s protocol (Promega, Madison, WI, USA). 10,000
A375 cells were seeded in a 96-well plate at and treated with compounds or DMSO for different time
points (24, 48 and 72 h). Afterwards, 100 µL of culture media of each well was transferred to a 96
white multi-well plate and 100 µL of Caspase-Glo® 3/7 reagent was added and incubated for 1 h at
room temperature. When the incubation period was completed, the luminescence of each sample
representing the enzymatic activity of caspase was measured using a plate-reading luminometer
(Tecan, Switzerland). The assay was performed in three independent experiments and each sample
was performed in triplicate (mean ± SD, n = 9).
2.7. Phase-Contrast and Fluorescence Microscopy
Morphological assessment of A375 cells was performed to detect the cellular changes induced by
the tested compounds according to the previously mentioned method, with slight modifications [23].
A375 cells were seeded at a density of 10,000 cells in a sterile chamber slide system (Lab-Tek™ II
chamber slide™ system, Nunc™, Rochester, NY, USA) with or without compounds/DMSO for 48 h.
Treated cells with typical morphological changes of apoptosis were imaged using a phase-contrast
inverted microscope (EVOS cell imaging system, Thermo Fisher Scientific, Waltham, MA, USA).
A375 cells were treated in the same condition and examined with a fluorescence microscope
using the ReadyProbes® cell viability imaging kit according to the manufacturer’s recommendations
(Thermo Fisher Scientific, Waltham, MA, USA). The dyes were added and incubated at 37 ◦C for 15 min
and the wells were visualised using the EVOS cell imaging system. The results were obtained by
capturing images for six random fields for each sample from three different experiments.
2.8. Western Blot Analysis
Changes of protein expression were investigated using Western blot application solution kit
according to the manufacturer’s recommendation (Cell Signalling Technology, Danvers, MA, USA).
After seeding A375 cells and treating them with compounds and DMSO for 48 h, cells were lysed,
sonicated and centrifuged, the supernatant was used to quantify the protein concentration using a
bicinchoninic acid (BCA) kit (Cell Signalling Technology, Danvers, MA, USA) as instructed by the
manufacturer. The protein (50 µg) was suspended in SDS sample buffer and loaded to SDS-PAGE gel
along with a prestained protein marker (11–190 kDa), in which electrophoresis was carried out at 110 V
for 95 min (PowerPac™ Basic power Bio-Rad, Hercules, CA, USA). The gel was transferred into a
nitrocellulose membrane in the same electrophoresis tank at 110 V for 95 min. After removing the
gel, the membrane was blocked in blocking buffer for 1 h at room temperature. Then, the membrane
was washed with TBST and probed with Bax, Bcl-2, and β-actin proteins, the latter was used as
a standard for the amount of the loaded protein (50 µg) in each lane. Later, the bound primary
antibody complex was stained using horseradish peroxidase-conjugated secondary antibodies. Protein
bands were detected with enhanced chemiluminescence reagents and visualised by GeneGnome for
chemiluminescence imaging (Syngene Bio Imaging, Frederick, MD, USA) using GENESys (version
1.3.3.0). Densitometric evaluation of change in expression levels of Bax/Bcl-2 proteins was carried
out using GelQuantNET (version 1.8.2). Data were expressed as the ratio of Bax and Bcl-2 that was
normalised to β-actin and the experiment was performed across three different passages (mean ± SD,
n = 3).
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2.9. Scratch Assay for Anti-Migratory Activity
This assay was carried out as described previously with slight modifications [24] using the B16-F10
cell line as it is a highly aggressive cell line to close the gap within a limited time. Around 250,000 cells
were plated on a 6-well plate to produce a nearly confluent cell monolayer and later a scratch was made
using a sterile 200 µL plastic pipette tip in the monolayer and wells were washed with the media to
remove the detached cells. Free serum medium containing DMSO, the compounds and combinations
were added and incubated for 24 h. Later, cells were fixed with 3.7% formaldehyde and representative
images for each well were taken with EVOS cell imaging system. The images were analysed using
TScratch software (ETH Zurich, Switzerland) and the potential synergistic effect of the combined drugs
was analysed using CalcuSyn software (Biosoft, Cambridge, UK). Data were expressed as the migration
rate of each sample relative to the control taken from four images over three independent experiments.
2.10. Transwell© Assay for Anti-Invasive Activity
Cell invasion was also measured using a Boyden chamber system as described previously [25].
Polycarbonate filters with an 8-µm pore size (6.5 mm, Corning, NY, USA) pre-coated with Matrigel were
placed to the top of Transwell filters in a 24-well plate. B16-F10 cells were seeded in serum-free medium
onto the pre-coated filters and the lower chambers were filled with the same medium containing several
concentrations of the drugs and incubated for 24 h. Later, the remaining cells were gently removed
using a cotton swab and the inserts were washed and fixed with cold methanol. Then, the migrated
cells were stained with 0.5% crystal violet for 30 min, then inserts were washed with PBS. The filter
was cut out and mounted on a microscopic slide with a coverslip using VALAP (vaseline, lanolin,
and paraffin) in which several images were taken using a light microscope (Nikon Microphot-FXA,
Nikon, Tokyo, Japan) using a Nikon digital camera (Nikon, Kingston upon Thames, UK). The number
of the cells that migrated to the lower side of the filter was determined using Infinity Capture software
(version 6.2) and presented as a percentage of invaded cells/field compared to the control (mean ± SD)
from three independent experiments.
2.11. Statistical Analysis
Results are expressed as mean ± standard deviation (SD) from at least three independent
experiments. All data were analysed using unpaired two-tailed Student’s t-test with a p-value of <0.05
considered as significant to find the statistical significance between treated groups and controls using
InStat v.3 (GraphPad, San Diego, CA, USA). Calcusyn software (Biosoft, Cambridge, UK) was used for
the calculation of synergies/antagonisms by the Chou-Talalay method [26].
3. Results
3.1. Effects on A375 Human Melanoma Cells Proliferation and Selectivity Towards Adult Human
Dermal Fibroblasts
The anti-proliferative effects were studied using the SRB assay on both A375 and HDf-a
cell lines (Figure 2). 3-O-acetylursolic acid and ursolic acid showed a significant time and
concentration-dependent suppression of cell proliferation at 32.4 ± 1.33 µM and 26.7 ± 3.61 µM,
respectively. They are comparatively non-toxic to HDf-a a shown by their relatively high GI50
concentrations (126.5 ± 24 µM for 3-O-acetylursolic acid and 89.31 ± 9.50 µM for ursolic acid).
The selectivity of 3-O-acetylursolic acid and ursolic acid towards HDf-a compared to A375 cells were 4-
and 3-fold, respectively.
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Figure 2. Anti-proliferative effect of 3-O-acetylursolic acid and ursolic acid on human melanoma A375
cells (upper row at 24, 48 and 72 h) and adult Human Dermal Fibroblasts HDf-a cells (lower row at
48 h) as assessed by the Sulforhodamine B assay. Data are presented as the mean ± SD (n = 3).
3.2. Effects on A375 Cell Cycle Distribution
Synchronised cells were assessed by flow cytometry after their exposure to GI50 doses of ursolic
acid and its acetate for 48 h, to evaluat whether inhibition on c ll proliferation is accompani d by any
effect on cell cycl progression. Cell cycle distributio in 3-O-acetylursolic acid-treated cells showed
a pronoun ed reduction of G1 population (58.70%, p = 0.0067) with a concomitant elevation of cell
population at S stage (28.94%, p = 0.0373) compared to untreated cells (Figure 3A). Treatment of
A375 cells with ursolic acid progressively increased the values of cell counts in sub-G1 phase (9.12%,
p = 0.0008) which were considered t b apoptoti cells due to the decrease in their DNA content
(Figure 3B).
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Figure 3. Cell-cycle analysis of human melanoma A375 cells exposed to GI50 concentrations of
3-O-acetylursolic acid (UAA) and ursolic acid (UA) at 48 h. (A) The percentage of cell population in
each stage of cell cycle. (B) Cell cycle distribution (control and treated) was analysed by measuring the
DNA content using flow cytometry. Data are shown as mean ± SD (n = 3).
3.3. Induction of Apoptosis According to Annexin V-FITC/Propidium Iodide (PI) Staining
To investigate whether apoptosis was triggered following exposure to the compounds,
phosphatidylserine translocation to the outer leaflet was examined by Annexin V-FITC and PI
double staining, after treatment GI50 of both compounds for 12 and 24 h. After 12 h treatment, no
significant effects were observed on the fluorescence intensity of Annexin V-FITC or PI for both
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compounds. Cellular exposure to 3-O-acetylursolic acid for 24 h led to an increase in the number of
Annexin V-positive/ PI-negative cells (3.99%, p = 0.0118), which was concomitant with a decrease in the
number of live cells (60.98%, p = 0.0077) (Figure 4A). Additionally, the percentage of double-positive
population Annexin V-positive/PI-positive was significantly increased (29.06%, p = 0.0153). In the case
of ursolic acid-treated cells, Figure 4B shows a significant Annexin V-positive/ PI-negative population
(5.40%, p = 0.0420), which was associated with a reduction in the percentage of the normal population
(54.65%, p < 0.0001). The magnitude of late apoptotic population (Annexin V-positive/ Pl-positive) was
greatly increased (28.67%, p = 0.0002) compared to untreated cells. The number of necrotic (Annexin
V-negative/ Pl-positive) cells was not significantly high and remained less than 10% for the entire
period of the experiment.
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3.4. Changes in Cell Morphology Associated with the Treatment 
A qualitative evaluation of cell viability was conducted using the ReadyProbes® cell viability 
imaging kit (blue/green) and phase contrast microscope to confirm that both compounds were 
cytotoxic to melanoma cells and to reflect the findings of the SRB assay. The percentage of green-
stained cells after exposure to ursolic acid and its acetate for 48 h were elevated compared to the 
control, indicating that both compounds promoted cell death (Figure 5 upper row). Additionally, 
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Figure 4. Flow cytometry analysis using Annexin V-FITC/propidium iodide (PI) double staining of
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3.4. Changes in Cell Morphology Associated with the Treatment
A qualitative evaluation of cell viability was conducted using the ReadyProbes® cell viability
imaging kit (blue/green) and phase contrast microscope to confirm that both compounds were cytotoxic
to melanoma cells and to reflect the findings of the SRB assay. The percentage of green-stained cells
after exposure to ursolic acid and its acetate for 48 h were elevated compared to the control, indicating
that both compounds promoted cell death (Figure 5 upper row). Additionally, phase contrast images
(Figure 5 lower row) show that untreated cells grew to near confluence and were able to spread
regularly in the slide, whereas cells treated with 3-O-acetylursolic acid displayed several apoptotic
features such as cell shrinkage and membrane blebbing over the incubation period. In the case of ursolic
acid-treated cells, morphological changes were detected but to a lesser extent than 3-O-acetylursolic
acid-treated cells, and this included a decrease in their size and a lack of cell-cell contact. Based on
these findings, the dramatic changes in cell morphology provide evidence that the acetyl group may
enhance the distinct morphological changes of apoptosis more in 3-O-acetylursolic acid-treated cells
than in ursolic acid-treated cells.
3.5. Induction of Caspase-3/7 Activity
As A375 cells underwent apoptosis after exposure to both compounds, the changes in caspase-3/7
were assessed where the cells were either treated with ursolic acid and its acetate, to evaluate whether the
anti-proliferative activity associated with effects on caspase-mediated apoptosis pathway. Caspase-3/7
activity was induced upon cell exposure to the GI50 values with time-dependent enhancement in the
treated cells. Both compounds promoted caspase-3/7 activity by 1.8-fold when compared to control
cells (p < 0.05) at 48 h (Figure 6).
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Figure 5. Microscopy analyses of human melanoma A375 cells after exposure to GI50 concentrations
of 3-O-acetylursolic acid (UAA) and ursolic acid (UA) during 48 h. (A) Representative fluorescence
images of stained cells with Hoechst 33342 and NucGreen® Dead reagent and light contrast microscopy
images (40×) of human melanoma A375 cells (control and treated). (B) Quantification of percentage of
dead cells (green cells) from three independent experiments. Bar = 100 µm.
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Figure 6. The caspase-3/7 activity of in human melanoma A375 cells treated with GI50 of 3-O-acetylursolic
acid (UAA) and ursolic acid (UA) at different incubation periods (24, 48, and 72 h). Data are presented
as the mean ± SD (n = 3), (*) p < 0.05.
3.6. Bax and Bcl-2 Expression in the Presence of Ursolic Acid and Its Acetate
Since Bax and Bcl-2 have a crucial role in apoptosis, Western blot analysis was performed to
determine the effects of GI50 concentrations of 3-O-acetylursolic acid and ursolic acid on the expression
level of both proteins in A375 c lls. Following 48 h treatment, ursolic acid and its acetate caus d an
alteration in the expression of Bax and Bcl-2 on A375 cells, leading to a sig ificant change in Bax/Bcl-2
ratio (p = 0.0017 and 0.0011, respectively). Bcl-2 was almost downregulated with simultaneous
upregulation of Bax protein (Figure 7) in comparison to their respective controls.Biomolec es 2020, 10, x FOR PEER REVIEW 9 of 14 
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Figure 7. (A) Immunoblot images of the expression Bax and Bcl-2 in human melanoma A375 cells after
48 h treatment with GI50 of 3-O-acetylursolic acid (UAA) and ursolic acid (UA). (B) Densitometric
evaluation of the expression levels of Bax/Bcl-2 proteins normalized to β-actin and changes in Bax/Bcl-2
ratio. Data are presented as the mean ± SD (n = 3), (**) p < 0.01.
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The anti-migratory properties were evaluated using scratch assay where a scratch was first
created in a monolayer of B16-F10 melanoma cells and the cells were treated with the test drugs.
The anti-migratory capacity of the single compounds was evaluated and their IC50 calculated (Table 1)
as shown by gap closure in Figure 8. Notably, 3-O-acetylursolic acid did not inhibit melanoma
migration, suggesting that the presence of the acetyl group diminishes the anti-migratory properties of
the parent molecule. 3-O-acetylursolic acid was not active in this model at concentrations up to 200 µM
(Data not shown). We therefore further tested the in vitro anti-invasive properties (3D migration) of
ursolic acid and quercetin in a Matrigel-coated Transwell model.Biomolecules 2020, 10, x FOR PEER REVIEW 10 of 14 
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Figure 8. 2D anti-migratory effects of 3-O-acetylursolic acid (UAA) and ursolic acid (UA) on B16-F10
murine melanoma cells alone and in fixed ratio combinations with quercetin. Representative microscopy
images showing gaps in a confluent cell monolayer immediately after scratching (0 h) and at 24 h
post-wounding (n = 3).
Table 1. Calculation of the synergy between ursolic acid and quercetin in the 2D migration assay. Data
are presented as the mean ± SD (triplicates of three separate passages).
Ratios Quercetin
µM
Ursolic Acid
µM
Relative
Migration
Combination
Index
Relative
Synergy 1
n/a 125 0 50% n/a n/a
n/a 0 13.7 50% n/a n/a
IC50 125 13.7 24% 0.90-1.10 ±
IC50/2 65.5 6.85 34% 0.7-0.85 ++
IC50/4 31.25 3.42 44% 0.3-0.7 +++
IC50/8 15.62 1.71 52% 0.3-0.7 ++
1 (±) Nearly additive; (++) Moderate Synergism; (+++) Synergism [26].
3.7. Effects of the Combination Treatments
Combination treatments of the triterpene acids and quercetin failed to show any synergy in
suppressing cell proliferation (data not shown).
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Due to the lack of anti-migratory activity of 3-O-acetylursolic acid, we only tested the combination
of ursolic acid with quercetin in cells exposed to ‘fixed ratios’ as follows: 1, 1/2, 1/4, and 1/8 of their
IC50s. Quantitative analyses of the relative migration rates are summarised in Table 1. The results
show that the IC50/2, IC50/4, and IC50/8 combinations significantly decreased cell migration during
the scratch assay (p < 0.05) and produced synergistic effects as indicated by the combination index
(CI) value.
The effect of the combinations at the same fixed ratios of both drugs on cell invasion is shown
in Figure 9. All combination treatments down to 1/8 IC50s significantly suppressed 3D cell B16-F10
melanoma cells movement. The results indicated that we could reduce the concentrations of combined
drugs to 1/4 without any significant loss of anti-invasive effects when compared with full IC50s.Biomolecules 2020, 10, x FOR PEER REVIEW 11 of 14 
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Figure 9. (A) Representative microscopy images (10×) showing invasive murine melanoma B16-F10 cells
after treatment with quercetin and ursolic acid (48 h) using Transwell© invasion assay. (B) Quantitative
data of the 3D invasion experiment. Data are presented as the mean ± SD (n = 3), (**) p < 0.01;
(***) p < 0.001.
4. Discussion
The above-presented results evidence for th first time that the 3- cetylation of ursolic acid changes
the phase at which A375 cells arrest their cel cycle. This occurs with a similar GI50 and ensitivity index
to the par t molecule. The blockage at the S-phase results in dramatic morphological cha ges during
the apoptotic phase not seen with ursolic acid, which arrests the cell cycle at the sub-G1 phase instead.
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Apart from this differential effect, the anti-proliferative effect of the two triterpenic acids follows
a similar timeline: treatment with both compounds induced early signs of apoptosis within 24 h,
as revealed by the elevated percentage of Annexin V-positive/ PI-negative cells (3.99% vs. 5.40%),
respectively. This is followed 24 h later by increased caspase-3 activity and disruption in the balance
between Bax and Bcl-2 expression in favour of Bax, thus suggesting the involvement of the mitochondrial
pathway in apoptotic death. This is consistent with previous studies for ursolic acid on non-small cell
lung cancer cells and M4Beu cells [7,27]. However, previous research has shown that changes in Bax
protein are dependent on the cancer cell line [28,29].
Previous research on melanoma M4Beu cells had shown how ursolic acid induces cell arrest
at sub-G1 or G1 phase (depending on the cell line) followed by mitochondrial-related apoptosis.
Strikingly, the anti-proliferative effect at 24 h and 48 h is not matched by a reduction of mitochondrial
viability [29,30]. A similar effect was described for the isoflavone genistein in MCF-7 cells [31].
The authors concluded that because genistein and UA are potent inhibitors of both tyrosine kinases
and topoisomerase II, these targets were related to the observed discrepancy [7].
The S-phase arrest induced by 3-O-acetylursolic acid is still compatible with the inhibition of
topoisomerase II, as seen by the effect of ciprofloxacin in COLO829 melanoma cells [32] suggesting
that the 3-acetylation changes the expression of cyclins and CDKs involved in S phase progression.
As DNA is replicated once during the S-phase, cells can neither go forward nor retreat to G1 stage [33].
This differential effect may be the cause of the dramatic changes induced by 3-O-acetylursolic acid in
cell morphology compared to ursolic acid-treated cells, featuring significantly higher cell shrinkage
and membrane blebbing.
Melanoma is highly metastatic cancer. Ursolic acid has been reported to inhibit melanoma
migration and angiogenesis [9] but we found here that 3-O-acetylursolic acid is devoid of any
significant effect on B16F10 cell migration, suggesting that the hydroxyl group is likely to be essential
for the anti-migratory effect of ursolic acid on these cells.
There is increased interest in combinatorial treatments of chemotherapy drugs with quercetin [20].
Previous work described how quercetin and sulforaphane were able to reduce melanoma growth in
a mouse model by suppressing MMP-9 expression in the mouse tumours [34]. As ursolic acid and
quercetin have been reported to display anti-migratory activity on melanoma cells, the potential effects
of combining both compounds on melanoma migration and invasion have been investigated. The results
revealed synergistic effects when UA combined with quercetin at a ratio 9:1. This combination markedly
reduced melanoma invasion at all tested concentrations, thus allowing for a reduction of the required
concentration up to four times less than their original IC50s. However, no anti-proliferative synergistic
effects were found between the triterpene acids and quercetin. In a natural products discovery context,
the ubiquity of these two compounds may explain the decrease of anti-migratory in vitro activities
when many crude extracts are fractionated into increasing polarity fractions.
5. Conclusions
In summary, 3-acetylation of ursolic acid maintains the potency and overall apoptotic mechanism
of the parent molecule with a more aggressive influence on the morphology of A375 melanoma cells
due to their arrest at S instead sub-G1 phase. We also demonstrate here that ursolic acid can act in
synergy with quercetin to reduce cancer cell migration.
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